In his lead opinion upholding the validity of Angiotech's patent, Lord Hoffmann did not agree with the reasoning that the UK lower courts used in justifying revocation and instead agreed with the opinion of the Dutch Court. The House of Lords' unanimous decision reflects an important development in bringing uniformity to the interpretation of the European Patent Convention among the national courts of Europe and the European Patent Office.
Note on Forward Looking Statements:
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the
words "believes," "may," "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects" and similar expressions, constitute
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995 and constitute "forward-looking
information" within the meaning of applicable Canadian securities laws. All
such statements are made pursuant to the "safe harbor" provisions of
applicable securities legislation. Forward-looking statements may involve,
but are not limited to, comments with respect to our objectives and
priorities for 2007 and beyond, our strategies or future actions, our
targets, expectations for our financial condition and the results of, or
outlook for, our operations, research development and product and drug
development. Such forward-looking statements involve known and unknown
risks, uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future results,
events or developments expressed or implied by
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved